---
title: Protocol of a first-in-human clinical trial to evaluate the safety, tolerability,
  and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with
  colorectal cancer (CoRe_CC-3)
date: '2024-02-27'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38410109/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240227170527&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'INTRODUCTION: Colorectal cancer (CRC) is the third most common cancer
  worldwide in men and women. In the metastasized stage, treatment options and prognosis
  are limited. To address the high medical need of this patient population, we generated
  a CD276xCD3 bispecific antibody termed CC-3. CD276 is expressed on CRC cells and
  on tumor vessels, thereby allowing for a "dual" anticancer ...'
disable_comments: true
---
INTRODUCTION: Colorectal cancer (CRC) is the third most common cancer worldwide in men and women. In the metastasized stage, treatment options and prognosis are limited. To address the high medical need of this patient population, we generated a CD276xCD3 bispecific antibody termed CC-3. CD276 is expressed on CRC cells and on tumor vessels, thereby allowing for a "dual" anticancer ...